ABSTRACT

Vitiligo is a common, acquired, pigmentary disorder of skin and hair resulting from the destruction of functional melanocytes. It is characterized by well-circumscribed, asymptomatic depigmented macules. Keloids is an abnormal wound responses in predisposed individuals and represent a connective tissue response to trauma, inflammation, surgery, or burns. Here, we report an unusual case of vitiligo juxta-keloid in a 46-year-old woman.

Keywords: Vitiligo, keloid, autoimmune

1. INTRODUCTION

Vitiligo is a disease in which patchy depigmentation of skin and hair results from autoimmune loss of melanocytes. It is a complex disorder involving multiple susceptibility genes and unknown environmental triggers. Genetic linkage and candidate-gene association studies have implicated several potentially contributory loci, though few have been consistently supported by the data (Jin et al. 2010). Keloids result from an abnormal fibrous wound healing process in which tissue repair and regeneration-regulating mechanism control is lost. These abnormal fibrous growths present a major therapeutic dilemma and challenge to the plastic surgeon because they are disfiguring and frequently recur (Wolfram et al. 2009). Here, we report a case of vitiligo juxta-keloid in a 46-year-old woman.
2. CASE REPORT
A 46-year-old housewife attended our department with symptomatic keloid on left shoulder since childhood. Later she developed gradually progressive, asymptomatic, whitish and non scaly macules on left shoulder and both lips of 8 years duration. Initially she developed the depigmented macule on both her lips later she noticed the similar lesions juxta-keloid (Figure 1, 2 & 3). Examination of scalp, and nails showed no abnormality. There was no history of any other illness, drug intake or intralesional therapy for a keloid. The diagnosis of vitiligo and keloid was made clinically.

3. DISCUSSION
This is an unusual case of development of vitiligo juxta-keloid in a female patient. Vitiligo is an idiopathic disease that causes destruction of melanocytes in the skin, mucous membranes, eyes, inner ear, leptomeninges and hair bulbs (Gopal et al. 2007). Although genetic, autoimmune, neurogenic and melanocyte self-destruction hypothesis have time and again been described in the etiopathogenesis of vitiligo. The occurrence of vitiligo after major illness, severe emotional stress, pregnancy, surgical operation and physical trauma has been recorded. Some noxious, melanocyte-destroying chemical entering the body through diet, consumption of readymade preserved stale food/medicines/contaminated water (through industrial waste) or the air might be an important factor in precipitation of vitiligo in a susceptible host. The occurrence of vitiligo following repeated drug intake in as many as 535 (26.75 per cent) patients is far more than just a coincidence, and warrants serious thought prior to prescribing antibiotic therapy in patients who have a family history of vitiligo (Behl et al. 1999). Patients vitiligo have elevated frequencies of other autoimmune diseases, including autoimmune thyroid disease, rheumatoid arthritis, psoriasis, adult-onset type 1 diabetes, pernicious anemia, systemic lupus erythematosus, and Addison's disease, suggesting that these diseases involve shared genetic components (Gopal et al. 2007). The disease is further classified according to distribution pattern and extent of depigmentation. The presence of several clinical subtypes may reflect the diversity in causative factors. To select appropriate therapeutic measures it is important to distinguish vitiligo from other disorders that affect melanocyte function. Although vitiligo has a characteristic clinical appearance and histological features, the presence of early or atypical lesions often requires the exclusion of other disorders such as postinflammatory hypopigmentation and piebaldism. Therapies aimed at repopulation of lesional skin include phototherapy, application of topical corticosteroids, and transplantation of skin or skin cells. Moreover, micropigmentation or camouflage can be used to restore a pigmented appearance to lesional skin (Le Poole et al. 1997).

Keloids develop as a result of an overgrowth of dense fibrous tissue after skin injury. When an imbalance occurs between the anabolic and catabolic phases of the healing process, more collagen is produced than is degraded, and the scar grows in all directions resulting in keloid formation (Jindal et al. 2010). Experimental evidence implicates the importance of members of the transforming growth factor β (TGF-β) family in cutaneous scarring, as well as scarring in other organs. Virtually every cell in the body, including epithelial, endothelial, hematopoietic, neuronal, and connective-tissue cells, produces TGF-β and has receptors for it. TGF-β regulates the proliferation and differentiation of cells, embryonic development, wound healing, and angiogenesis. TGF-β directly stimulates angiogenesis in vivo. TGF-β is released by platelets at the site of injury. Aberrations in the levels of cytokines, including interleukins 6, 13 and 15 may also have a role in keloid formation. Although TGF-β is essential for wound healing, overproduction of TGF-β can result in excessive deposition of scar tissue and fibrosis (Mutalik et al. 2005). The most commonly used modalities are pressure, silicone gel sheet, intralesional steroids, 5-fluorouracil (5 FU), cryotherapy, surgical excision, and lasers. They may be used either singly or, as is done more commonly, in combinations (Gupta et al. 2011).
4. CONCLUSION

Case study has been made as it is a very rare case and interesting clinically. Vitiligos in association with multiple sclerosis, cutaneous amyloidosis, twenty-nail dystrophy linear scleroderma, Parry-Romberg syndrome, naevoid basal cell carcinoma syndrome, have been reported (Bhargava et al. 1995, Bhargava et al. 2001, Rajashekar et al. 2008, Bonifati et al. 2006, Creus et al. 1994, Muramatsu et al. 2005). The association of vitiligo juxta-keloid is very rare and has not been reported, which prompted us to report this case.

REFERENCES

11. Mutalik S. Treatment of keloids and hypertrophic scars. Indian J Dermatol Venereol Leprol. 2005, 71, 3-8